The LACTEL 50:50 DL-PLG (B6029-2) Biomedical PLGA Copolymer is a poly(DL-lactide-co-glycolide) resin in which the nominal 50:50 molar ratio of DL-lactide to glycolide repeat units creates an amorphous, water-insoluble but hydrolytically degradable backbone. The B6029-2 grade is controlled to a low inherent-viscosity band, with the certificate of analysis typically reporting 0.15–0.25 dL/g when measured as a 0.1% w/v solution in chloroform at 25 °C; the exact viscometer conditions and solvent temperature must be taken from the lot-specific CoA. The DL-lactide comonomer disrupts crystallinity, so the material does not show the melting endotherm associated with poly(L-lactide)-rich grades. Hydrolysis of the ester linkages generates lactic acid and glycolic acid. The low-viscosity, relatively fast-degrading profile is intended for solvent-based drug-delivery processes such as microsphere encapsulation, nanoparticle precipitation, and injectable in situ forming matrices. Sealed packages should be stored desiccated at −20 °C under inert gas and allowed to reach ambient temperature before opening to avoid moisture condensation. The grade name does not remove the requirement for end-group verification; an acid-terminated lot will hydrate and erode differently from an ester-capped lot of similar viscosity.

Why Does Inherent Viscosity Control Dominate B6029-2 Process Selection?

The 0.15–0.25 dL/g inherent-viscosity band is a practical surrogate for molecular weight and is the principal reason the B6029-2 grade is assigned to low-viscosity formulation routes. Because intrinsic viscosity scales with molecular weight through the Mark-Houwink relationship, small lot-to-lot differences within the band alter organic-phase viscosity, droplet breakup during emulsification, and the resulting particle-size distribution. A difference of 0.05 dL/g within the allowed band can be sufficient to change mean microsphere size if emulsification speed is not adjusted. The lower chain length yields reduced chain entanglement and lower extensional viscosity in fibre-forming processes. A low-IV polymer permits higher polymer loading in dichloromethane, ethyl acetate, or acetone while retaining a syringeable, filtrable organic phase; this is useful when the process requires passage through a 0.22 μm membrane or when a high ratio of polymer to solvent is needed to reduce solvent load. For implants requiring longer mechanical integrity, a higher-IV 50:50 PLGA or a higher lactide ratio should be evaluated. The B6029-2 viscosity band should not be interpreted as a single molecular-weight value; a GPC baseline with polystyrene-equivalent or universal calibration must be established for each incoming lot.

In an oil-in-water microsphere process, B6029-2 is typically dissolved at 10–25 wt% in dichloromethane and dispersed into an aqueous poly(vinyl alcohol) continuous phase at 0.5–2 wt% using a rotor-stator mixer operating between 5,000 rpm and 10,000 rpm. The low organic-phase viscosity reduces viscous resistance at the rotor tip, so higher rotor speeds or longer emulsification times may be required to obtain mean particle diameters below 20 μm. In a 1 L jacketed reactor, the primary emulsion is transferred under moderate impeller agitation of 300–600 rpm, and solvent is removed at 25–35 °C under reduced pressure. Cooling the hardening bath to 2–8 °C can slow coalescence and reduce burst release. Particle size also depends on poly(vinyl alcohol) hydrolysis degree, oil-to-water ratio, and the presence of co-solvents such as ethyl acetate or dimethylformamide; therefore the B6029-2 viscosity alone is not a complete predictor of microsphere diameter. Batch-to-batch differences in polymer viscosity will propagate into final particle diameter if the emulsification speed is not adjusted against the CoA viscosity.

Residual Monomer, Tin, and Solvent Limits for Injectable-Grade Use

After solvent removal, the finished parenteral dosage form is evaluated for residual DL-lactide, glycolide, tin catalyst, and organic solvent, but the selection of a medical-grade raw polymer such as B6029-2 affects the analytical burden. A lot-specific CoA should report residual monomers by gas chromatography with flame ionisation detection or by ¹H NMR; for injectable use, total residual lactide and glycolide may be agreed below 1.0 wt%, although regional pharmacopoeial or compendial limits may differ. Residual tin from stannous octoate polymerisation is commonly controlled in the low-ppm range for absorbable drug-delivery polymers; if a low-tin specification is required, it must be requested at the purchasing stage because not every catalogue grade is released against the same limit. Organic solvent residue is determined by headspace gas chromatography and should be evaluated against ICH Q3C or regional pharmacopoeial requirements for the finished product. The polymer itself is not a terminally sterile product, and a USP <71> sterility claim is not meaningful for the raw resin; biological safety is assessed under ISO 10993-1 for the finished device or drug-delivery system.

Residual solvent clearance in downstream processing is dominated by drying geometry, film thickness, and vacuum profile rather than solely by the raw polymer. In a solvent-cast film or microsphere batch, dichloromethane can be reduced below the 600 ppm class-2 limit only after staged vacuum drying, aqueous washing, or spray drying; published data for this specific B6029-2 configuration are limited. Karl Fischer titration per ASTM E1064 should be used to monitor residual water before organic processing because water above 0.1 wt% accelerates hydrolytic damage during storage and thermal steps. A formulator should not assume that a low-viscosity PLGA automatically yields a low residual solvent level after drying, because the mass-transfer path and glassy skin formation often control the final result.

When Melt Processing or Electrospinning Is Required

If melt processing of B6029-2 is attempted, the low chain length limits melt strength, strand formation, and pelletization compared with higher-IV PLGA grades. The resin should be vacuum-dried at 35 °C until Karl Fischer moisture is below 0.1 wt%; exposure above 45 °C for extended periods can initiate chain scission before the material reaches the die. Differential scanning calorimetry at 10 K/min under nitrogen usually shows a single glass transition for dry 50:50 PLGA between 35 °C and 50 °C; no melting endotherm is observed because the DL-lactide segment disrupts crystallinity. In electrospinning, B6029-2 is more commonly dissolved in 10–20 wt% dichloromethane with a small amount of dimethylformamide to adjust conductivity and evaporation; fibre diameter depends on applied voltage, tip-to-collector distance, and solution viscosity. A single-screw extruder with 25:1 L/D may be used for compounding, but the absence of high melt viscosity increases sensitivity to screw drag and residence-time distribution. Avoid basic or nucleophilic additives because they accelerate ester cleavage; the resulting molecular-weight loss is irreversible.

Hydrolytic Degradation, Mass Loss, and In Vitro Release Benchmarks

The 50:50 lactide-to-glycolide ratio is a faster-degrading composition than 75:25 or 85:15 PLGA because the glycolide content increases hydrophilicity and water uptake. In phosphate-buffered saline at pH 7.4 and 37 °C, published studies on low-inherent-viscosity 50:50 PLGA grades report initial mass loss in the 2–4 week range and substantial mass loss by 6–8 weeks; film thickness, porosity, and local pH buffering shift these boundaries. If the B6029-2 lot is acid-terminated, the carboxylic acid end groups further increase water uptake relative to an ester-capped polymer of similar molecular weight, raising the rate of autocatalytic degradation and shortening the erosion lag phase. This property is advantageous in drug-eluting microspheres and short-term implants, but it is not appropriate for load-bearing scaffolds requiring long-term mechanical strength. In vitro release from similar 50:50 PLGA matrices often shows an initial burst of 5–30% within 24 h, depending on drug loading, encapsulation efficiency, particle size, and polymer end-group chemistry. The measured release is not an intrinsic property of B6029-2 alone; it emerges from the microsphere or implant architecture.

When degradation proceeds in a poorly buffered microenvironment, the accumulation of lactic and glycolic acid can depress local pH below 4, producing autocatalytic acceleration and pH-dependent drug destabilisation. Incubation in 50 mM phosphate or bicarbonate buffered at pH 7.4 slows this pH drift compared with unbuffered saline, but it does not eliminate it inside thick PLGA devices. For B6029-2 matrices above roughly 1 mm thickness, internal acid accumulation can produce heterogeneous degradation with a hollow interior and a more intact surface layer. Process development should therefore include cross-sectional scanning electron microscopy and pH mapping when long-term release studies are designed, because the low-viscosity grade hydrates rapidly and reaches the autocatalytic stage earlier than higher-IV counterparts. Where a standardised comparison is required, ASTM F1635 can provide a framework for mass-loss and molecular-weight retention testing, provided the test geometry and medium are fixed.

What Process Limits Arise from Low Molecular Weight in Aqueous Formulation?

Aqueous formulation with B6029-2 encounters two linked limits: the polymer is insoluble in water, and the low molecular weight accelerates hydrolysis once the dry polymer contacts an aqueous continuous phase. In a double-emulsion water-in-oil-in-water process, the primary water phase must be kept small and buffered because the low-viscosity PLGA shell can lose integrity during solvent removal, causing burst release and irregular pore formation. The organic phase should be filtered through a 0.22 μm membrane before primary emulsification; however, if the solution is too dilute, low viscosity may reduce droplet shear and broaden the size distribution. Typical organic-phase concentrations of 10–20 wt% are used to balance filterability and particle hardening. After solvent extraction, the glass transition of wet B6029-2 is depressed by plasticisation; this can cause particle deformation in a too-rapid vacuum-drying step. For long-term aqueous storage of the raw polymer, even refrigerated conditions above 0 °C are not appropriate once the package is opened; the opened material should be consumed immediately or stored under dry argon at −20 °C.

For scale-up, incoming B6029-2 lots should be qualified by viscosity, GPC molecular-weight distribution, residual monomer, and, if relevant to the finished product, residual tin and heavy metals. The raw polymer is not considered a finished drug product; manufacturing should follow 21 CFR 210/211 or ISO 13485:2016 according to the eventual clinical or commercial route. The product is differentiated from high-viscosity 50:50 PLGA grades by lower organic-phase viscosity and faster erosion, from 75:25 and 85:15 grades by the more hydrophilic 50:50 backbone, and from ester-capped grades by the acid-terminated end-group chemistry when the CoA confirms acid termination. Batch-to-batch variability in residual monomer and molecular weight must be handled through incoming-material specifications rather than by assuming equivalence of all 50:50 PLGA suppliers. Published data for the exact B6029-2 catalogue designation are limited; use lot-specific certificates and application-specific validation data for regulatory submissions.